[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100492877":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":15,"responsibleParty":55,"collaborators":7,"id":57,"slug":7,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":7,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":7,"enrollmentInfo":65,"targetDuration":7,"studyType":68,"phases":7,"briefSummary":69,"conditions":70,"keywords":7,"overallStatus":18,"whyStopped":7,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Intellia Therapeutics","INDUSTRY",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":13,"email":14},"Trial Manager at Intellia","CONTACT","1-857-285-6200","Ext. 6","medicalinformation@intelliatx.com",[16,28,37,46],{"facility":17,"status":18,"city":19,"state":7,"zip":7,"country":20,"countryCode":21,"cosmosGeoPoint":22,"geoPoint":27,"contacts":7},"Clinical Trial Site","RECRUITING","Paris","France","FR",{"type":23,"coordinates":24},"Point",[25,26],2.3488,48.85341,{"lat":26,"lon":25},{"facility":17,"status":18,"city":29,"state":7,"zip":7,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":36,"contacts":7},"Auckland","New Zealand","NZ",{"type":23,"coordinates":33},[34,35],174.76349,-36.84853,{"lat":35,"lon":34},{"facility":17,"status":18,"city":38,"state":7,"zip":7,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":45,"contacts":7},"Umeå","Sweden","SE",{"type":23,"coordinates":42},[43,44],20.25972,63.82842,{"lat":44,"lon":43},{"facility":17,"status":18,"city":47,"state":7,"zip":7,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":54,"contacts":7},"London","United Kingdom","UK",{"type":23,"coordinates":51},[52,53],-0.12574,51.50853,{"lat":53,"lon":52},{"type":56,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100492877",false,"NCT05697861","Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001","Long-Term Follow-Up of Subjects Treated With NTLA-2001","Inclusion Criteria:\n\n1. A subject has completed or discontinued from an Intellia-sponsored clinical study in which a complete or partial dose of NTLA-2001 was received.\n2. A subject has provided informed consent for the LTFU study.\n\nExclusion Criteria:\n\nNone","ALL","18 Years",{"count":66,"type":67},72,"ESTIMATED","OBSERVATIONAL","This is a follow-up study of subjects who received NTLA-2001 in a previous clinical trial as an observational evaluation of the long-term effects of the investigational therapy.",[71,72,73],"Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy","Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy","Wild-Type Transthyretin Cardiac Amyloidosis","2025-08-20",{"date":76,"type":77},"2025-08-26","ACTUAL",{"date":79,"type":77},"2023-07-10",{"date":81,"type":67},"2038-03",{"name":5,"class":6},4]